Zhao Wenyuan, Chen Sue S, Chen Yuanjian, Ahokas Robert A, Sun Yao
Division of Cardiovascular Diseases, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tenn 38163, USA.
Am J Nephrol. 2008;28(4):548-54. doi: 10.1159/000115289. Epub 2008 Feb 1.
Fibrosis of the glomerulus and the tubulointerstitium occurs in patients with hypertension. Studies have shown that renal oxidative stress appears in hypertensive kidney disease. The potential role of oxidative stress in renal fibrogenesis remains to be elucidated. Herein, we tested the hypothesis that oxidative stress contributes to the development of renal fibrosis during hypertension.Sprague-Dawley rats received angiotensin II (AngII; 9 microg/h s.c.) for 4 weeks with/without co-treatment of antioxidants, apocynin and tempol (120 mg/kg/day each, p.o.). Untreated rats served as controls. Appearance of renal oxidative stress and its effect on the expression of transforming growth factor (TGF)-beta(1), population of myofibroblasts, collagen synthesis/degradation and fibrosis in kidneys were examined. Chronic AngII infusion elevated systemic blood pressure (228 +/- 6 mm Hg), which was accompanied with extensive renal fibrosis and oxidative stress represented as upregulated NADPH oxidase and suppressed superoxide dismutase (SOD). Co-treatment with antioxidants led to: (1) markedly decreased renal NADPH oxidase; (2) significantly attenuated gene expression of TGF-beta(1), type I collagen, and tissue inhibitors of matrix metalloproteinase (TIMP)-I/-II in the kidney; (3) largely reduced population of myofibroblasts in both the cortex and medulla; (4) significantly reduced renal collagen volume, and (5) partially suppressed blood pressure (190 +/- 8 mm Hg). Thus, prolonged AngII administration promotes renal oxidative stress, which is associated with hypertensive renal disease. AngII induces renal oxidative stress by increasing NADPH oxidase and reducing SOD in the kidney, which, in turn, upregulates collagen synthesis, while suppressing collagen degradation, thereby promoting the development of fibrosis in kidneys of hypertensive rats.
高血压患者会出现肾小球和肾小管间质纤维化。研究表明,高血压肾病中会出现肾脏氧化应激。氧化应激在肾脏纤维化形成中的潜在作用仍有待阐明。在此,我们验证了氧化应激在高血压期间促进肾脏纤维化发展这一假说。将Sprague-Dawley大鼠分为两组,一组皮下注射血管紧张素II(AngII;9微克/小时),持续4周,另一组在注射AngII的同时口服抗氧化剂阿朴脂蛋白和Tempol(各120毫克/千克/天),未接受治疗的大鼠作为对照。检测了肾脏氧化应激的出现情况及其对转化生长因子(TGF)-β(1)表达、肌成纤维细胞数量、肾脏胶原合成/降解及纤维化的影响。长期输注AngII可使全身血压升高(228±6毫米汞柱),同时伴有广泛的肾脏纤维化和氧化应激,表现为NADPH氧化酶上调和超氧化物歧化酶(SOD)受抑制。抗氧化剂联合治疗导致:(1)肾脏NADPH氧化酶显著降低;(2)肾脏中TGF-β(1)、I型胶原和基质金属蛋白酶组织抑制剂(TIMP)-I/-II的基因表达明显减弱;(3)皮质和髓质中的肌成纤维细胞数量大幅减少;(4)肾脏胶原体积显著降低;(5)血压部分得到抑制(190±8毫米汞柱)。因此,长期给予AngII可促进肾脏氧化应激,这与高血压肾病相关。AngII通过增加肾脏中的NADPH氧化酶和降低SOD来诱导肾脏氧化应激,进而上调胶原合成,同时抑制胶原降解,从而促进高血压大鼠肾脏纤维化的发展。